Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.76 |
| ▸ | RECQL | P46063 | 1/20 | 0.76 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.76 |
| ▸ | RAB9A | P51151 | 5/20 | 0.67 |
| ▸ | NPC1 | O15118 | 4/20 | 0.67 |
| ▸ | POLB | P06746 | 2/20 | 0.65 |
| ▸ | HPGD | P15428 | 3/20 | 0.64 |
| ▸ | DDX3X | O00571 | 2/20 | 0.62 |
| ▸ | ITGB3 | P05106 | 2/20 | 0.61 |
| ▸ | ITGAV | P06756 | 2/20 | 0.61 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.61 |
| ▸ | ITGA5 | P08648 | 1/20 | 0.61 |
| ▸ | MAPT | P10636 | 3/20 | 0.57 |
| ▸ | TP53 | P04637 | 1/20 | 0.57 |
| ▸ | GAA | P10253 | 1/20 | 0.57 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.57 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.57 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.57 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1275926 | 0.89 | RAB9A (0.75) | ALDH1A1RAB9ANPC1POLBHPGD | |
| SCHEMBL14003501 | 0.87 | ALDH1A1 (1.00) | ALDH1A1RECQLSMN1; SMN2RAB9ANPC1 | |
| SCHEMBL6857852 | 0.83 | NPC1 (0.88) | ALDH1A1RECQLSMN1; SMN2RAB9ANPC1 | |
| SCHEMBL11057754 | 0.82 | POLB (0.63) | ALDH1A1RECQLSMN1; SMN2RAB9ANPC1 | |
| SCHEMBL5475011 | 0.82 | POLB (0.68) | ALDH1A1RAB9ANPC1POLBHPGD | |
| SCHEMBL8334833 | 0.82 | RAB9A (0.64) | ALDH1A1RAB9ANPC1POLBHPGD | |
| SCHEMBL8421705 | 0.82 | RAB9A (0.64) | ALDH1A1RAB9ANPC1POLBHPGD | |
| SCHEMBL14401688 | 0.81 | ALDH1A1 (0.60) | ALDH1A1RECQLSMN1; SMN2RAB9ANPC1 | |
| SCHEMBL9686399 | 0.81 | ALDH1A1 (0.60) | ALDH1A1RECQLSMN1; SMN2RAB9ANPC1 | |
| SCHEMBL28416832 | 0.81 | ALDH1A1 (0.87) | ALDH1A1RECQLSMN1; SMN2RAB9ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10351522-B2 | Sulfonamide derivative and pharmaceutically acceptable acid addition salt thereof | UNIVERSITY OF TSUKUBA (JP) | 2019-07-16 | — | — | US | disclosed |
| US-20180179151-A1 | SULFONAMIDE DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE ACID ADDITION SALT THEREOF | UNIVERSITY OF TSUKUBA (JP) | 2018-06-28 | — | — | US | disclosed |
| EP-3309146-A1 | SULFONAMIDE DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE ACID ADDITION SALT THEREOF | University of Tsukuba (JP) | 2018-04-18 | — | — | EP | disclosed |
| US-20140163028-A1 | INHIBITION OF ACTIVATED CDC42-ASSOCIATED KINASE 1 | INSTITUTE FOR CANCER RESEARCH D/B/A THE RESEARCH INSTITUTE OF FOX CHASE CANCER CENTER (US) | 2014-06-12 | — | — | US | disclosed |
| US-8658655-B2 | Inhibition of activated cdc42-associated kinase 1 | FOX CHASE CANCER CENTER (US) | 2014-02-25 | — | — | US | disclosed |
| US-20120245173-A1 | INHIBITION OF ACTIVATED CDC42-ASSOCIATED KINASE 1 | Reaction Biology Corporation (US) | 2012-09-27 | — | — | US | disclosed |
| WO-2009076434-A1 | INHIBITORS OF INTEGRIN VLA-4 | MOLECULAR INSIGHT PHARMACEUTICALS, INC. (US) | 2009-06-18 | — | — | WO | disclosed |
| WO-2003030889-A1 | PARA-AMINO BENZOIC ACIDS AS INTEGRIN ANTAGONISTS | BAYER HEALTHCARE AG (DE) | 2003-04-17 | — | — | WO | disclosed |
| US-5614498-A | OLIGOPEPTIDES, BRONCHDILATORS | BANYU PHARMACEUTICAL CO., LTD. (JP) | 1997-03-25 | — | — | US | disclosed |
| US-5496928-A | Endothelin antagonistic substance | BANYU PHARMACEUTICAL CO., LTD. (JP) | 1996-03-05 | — | — | US | disclosed |
| EP-0555537-A2 | Endothelin antagonistic substance | BANYU PHARMACEUTICAL CO., LTD. (JP) | 1993-08-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180179151-A1 | SULFONAMIDE DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE ACID ADDITION SALT THEREOF | HCRTR2, HCRTR1, NPSR1 | ALDH1A1 968/4885RECQL 4804/4885SMN1; SMN2 1062/4885 |
| US-20120245173-A1 | INHIBITION OF ACTIVATED CDC42-ASSOCIATED KINASE 1 | TNK2, CDC42BPA, CDC42BPG | ALDH1A1 4776/4885RECQL 3121/4885SMN1; SMN2 3783/4885 |
| US-10351522-B2 | Sulfonamide derivative and pharmaceutically acceptable acid addition salt thereof | HCRTR2, HCRTR1, NPSR1 | ALDH1A1 968/4885RECQL 4804/4885SMN1; SMN2 1062/4885 |
| US-20140163028-A1 | INHIBITION OF ACTIVATED CDC42-ASSOCIATED KINASE 1 | TNK2, CDC42BPA, CDC42BPG | ALDH1A1 4776/4885RECQL 3121/4885SMN1; SMN2 3783/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.